Description of organizationlogo

BIONEXT is a French SME created in April 2009 with 10 associates of complementary skills and benefiting from 10 years research in Structural System Biology and integration of OMICS data. Our mission is to combine novel algorithms and computing strategies to the everincreasing biological and clinical data to better understand and treat various diseases.

Close to several academics thanks to National and European projects, BIONEXT has developped pioneer models of more than 300 human cells and organelles, up to the atomic level. Those models are used to detail the complex dynamical networks of human cells and explore recognition specifity. In particular, our patented platform BVS (Bionext Virtual Screening) uses these models for the discovery of novel anti-targets of drugs which are responsible for untested mechanisms often linked to unpredicted side-effects, toxicity and lack of efficacy. The goal then is to enter a “Led Rescue Strategy” (LRS) that uses this new knowledge to lower the side-effects of the drug (or any compound) while increasing its selectivity and effectiveness for a given human cell.

With several international collaborative projects, BIONEXT is actively engaged in cutting-edge Science in Personalized Medicine.


Previous experience

Scientists and engineers in BIONEXT are specialized in System Biology, Bioinformatics, Genome Annotation, Chemoinformatics and Structural Biology. They are used to develop visualization and integrative analysis tools, as well as predictive models of various biological/chemical properties. In particular, BIONEXT develops and uses several advanced geometrical models for the fast, robust and sensitive integrative analysis of molecular structures. An example of development is our visualization software of 3D molecules, working on any computer and as an applet. Linked to several databases, it can perform integrative analysis to characterize dynamical molecular networks and create “Structural Annotations” (detailed 3D molecular animations detailing different mechanisms). Examples of those structural annotations:




Five recent publications relevant to the project

1) A computer platform associated to genetic data for personalized medicine,
Albou L.P., 2012, French Patent

2) SM2PH-db: an interactive system for the integrated analysis of phenotypic consequences of
missense mutations in proteins involved in human genetic diseases,
Friedrich A. et al, Human Mutation 2010

3) Method for characterizing a molecule,
Albou L.P., 2009, PCT Patent 2011/009964

4) Defining and characterizing protein surface using alpha shapes,
Albou L.P. et al, Proteins 2009

5) M-ORBIS: mapping of molecular binding sites an surfaces,
Albou L.P. et al, Nucleic Acid Research, 2011